Equities

Shanghai Hile Bio-Technology Co Ltd

603718:SHH

Shanghai Hile Bio-Technology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)8.25
  • Today's Change-0.33 / -3.85%
  • Shares traded16.14m
  • 1 Year change-26.67%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments350393539
Total Receivables, Net90105125
Total Inventory103145143
Prepaid expenses8.991416
Other current assets, total118.48152
Total current assets563665975
Property, plant & equipment, net165220306
Goodwill, net225224224
Intangibles, net3874100
Long term investments639315225
Note receivable - long term------
Other long term assets------
Total assets1,6581,5141,844
LIABILITIES
Accounts payable304339
Accrued expenses8.862234
Notes payable/short-term debt280162496
Current portion long-term debt/capital leases0.839.862.01
Other current liabilities, total978398
Total current liabilities417321670
Total long term debt0152.62
Total debt281187501
Deferred income tax1.471.372.12
Minority interest(42)(29)(18)
Other liabilities, total6466182
Total liabilities441374838
SHAREHOLDERS EQUITY
Common stock658644644
Additional paid-in capital230140132
Retained earnings (accumulated deficit)398372250
Treasury stock - common(66)----
Unrealized gain (loss)(2.57)(16)(20)
Other equity, total------
Total equity1,2171,1401,006
Total liabilities & shareholders' equity1,6581,5141,844
Total common shares outstanding644644644
Treasury shares - common primary issue1400
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.